Developing a New qPCR‐Based System for Screening Mutation
Abstract
An accurate genotyping analysis is one of the critical prerequisites for lung cancer targeted therapy. Here, a quantitative polymerase chain reaction (qPCR)‐based mutation detection system, mutation‐selected amplification‐specific system PCR (MASS‐PCR), is developed. The specific primers and probes used in MASS‐PCR exactly match with the mutant sequence that only allows mutant gene to emit the fluorescence peak. To determine the sensitivity of MASS‐PCR, 717 lung cancer specimens, 61 formalin‐fixed paraffin‐embedded (FFPE) tissues, and 656 fresh reaction tissues are collected and undergo mutation detection of lung cancer driver genes (EGFR, KRAS, BRAF, HER2, MET, ALK, and ROS1). These samples are divided into two groups. Mutations in Group I, which has 631 fresh reaction tissues, are analyzed by MASS‐PCR and the amplification refractory mutation system PCR (ARMS‐PCR). While group II samples, 25 fresh reaction tissues and 61 FFPE tissues, are screened through MASS‐PCR and next‐generation sequencing (NGS). All results are verified by direct sequencing. MASS‐PCR shows high consistency with ARMS‐PCR (kappa value > 0.733) and NGS (kappa value = 0.79) (P < 0.001). For the samples with inconsistent MASS‐PCR and ARMS‐PCR results, DS results more likely support the MASS‐PCR results. These data suggest that MASS‐PCR is a convenient, accurate, and economical method for the detection of lung cancer driver gene mutations in clinical practice.Keywords
Funding Information
- National Natural Science Foundation of China (81502383, 81602412, 51872205, 81400056, 81602000, 81703847)
- Foundation of Shanghai Municipal Commission of Health and Family Planning (2017YQ050, 2016Y0121)
This publication has 16 references indexed in Scilit:
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 studyThe Lancet Oncology, 2015
- Clinical Utility of Droplet Digital PCR for Human CytomegalovirusJournal of Clinical Microbiology, 2014
- Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patientsMedical Oncology, 2014
- Taking qPCR to a higher level: Analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolutionMethods, 2010
- Personalized copy number and segmental duplication maps using next-generation sequencingNature Genetics, 2009
- Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testingNature Medicine, 2008
- Highly accurate SNP genotyping from historical and low‐quality samplesMolecular Ecology Notes, 2007
- Sensitive Sequencing Method for KRAS Mutation Detection by PyrosequencingThe Journal of Molecular Diagnostics, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- DNA sequencing with chain-terminating inhibitorsProceedings of the National Academy of Sciences, 1977